Show simple item record

dc.contributor.authorMurnane, Darragh
dc.contributor.authorMarriott, Christopher
dc.contributor.authorMartin, Gary P.
dc.date.accessioned2013-01-11T14:59:05Z
dc.date.available2013-01-11T14:59:05Z
dc.date.issued2008-05
dc.identifier.citationMurnane , D , Marriott , C & Martin , G P 2008 , ' Developing an environmentally benign process for the production of microparticles : Amphiphilic crystallization ' , European Journal of Pharmaceutics and Biopharmaceutics , vol. 69 , no. 1 , pp. 72-82 . https://doi.org/10.1016/j.ejpb.2007.10.014
dc.identifier.issn0939-6411
dc.identifier.urihttp://hdl.handle.net/2299/9589
dc.description.abstractThe production of microparticles for inhalation typically employs jet-milling which can be destructive to the solid-state properties of the particles. The objective of the current work was to develop a crystallization process for the production of respirable microparticles of salmeterol xinafoate (SX) with a controlled particle size distribution (PSD). Solvation of SX in aqueous poly(ethylene glycol) 400 (PEG 400) was investigated using HPLC and FTIR. SX was crystallized from PEG 400 solutions by the addition of water under a variety of conditions of supersaturation, addition rate of antisolvent and stirring speed. The crystals were filtered, dried at 50 degrees C and their PSDs were determined by laser diffraction. A logarithmic increase in solubility of SX was observed with increasing concentration of PEG 400 in water enabling the aqueous antisolvent crystallization of SX from PEG. Similar to antisolvent crystallization from conventional solvents, a 2(4) factorial study showed the particle size to decrease with increasing supersaturation. The PSD also depended on the balance of meso- and micromixing determined by the crystallization conditions. In particular a high addition rate (200 g min(-1)) and low stirrer speed (400 rpm) minimized the median diameter (2.54 +/- 0.40 mu m) and produced a narrow PSD (90% < 8.67 +/- 0.77 mu m) of SX particles. Amphiphilic crystallization provided a novel, environmentally benign method to produce microparticles of SX with a controlled size range. (C) 2007 Elsevier B.V. All rights reserved.en
dc.format.extent11
dc.format.extent320551
dc.language.isoeng
dc.relation.ispartofEuropean Journal of Pharmaceutics and Biopharmaceutics
dc.subjectcrystallization
dc.subjectantisolvent micronization
dc.subjectfactorial design
dc.subjectpoly(ethylene glycol)
dc.subjectsalmeterol xinafoate
dc.subjectINVERSE GAS-CHROMATOGRAPHY
dc.subjectMETERED-DOSE INHALERS
dc.subjectDRY POWDER INHALERS
dc.subjectDRUG-DELIVERY
dc.subjectPOLYETHYLENE-GLYCOLS
dc.subjectSURFACE ENERGETICS
dc.subjectPOLY(ETHYLENE GLYCOL)
dc.subjectPRECIPITATION PROCESS
dc.subjectSALMETEROL XINAFOATE
dc.subjectPULMONARY DELIVERY
dc.titleDeveloping an environmentally benign process for the production of microparticles : Amphiphilic crystallizationen
dc.contributor.institutionDepartment of Pharmacy
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionHealth & Human Sciences Research Institute
dc.contributor.institutionCentre for Research into Topical Drug Delivery and Toxicology
dc.contributor.institutionPharmaceutics
dc.contributor.institutionAirway Group
dc.contributor.institutionPharmaceutical Analysis and Product Characterisation
dc.description.statusPeer reviewed
rioxxterms.versionofrecord10.1016/j.ejpb.2007.10.014
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record